Adam Taich, Chief Financial Officer of 10x Genomics, Inc. (NASDAQ:TXG), filed a Form 4 on September 11, 2026, disclosing the sale of 46,388 shares of Class A Common Stock on September 9, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Three sale tranches: Adam Taich disposed of 1,206 shares, 31,428 shares, and 13,754 shares of Class A Common Stock, all on September 9, 2026.
  • Weighted average prices: The three tranches carried weighted average sale prices of $63.6774, $64.3097, and $65.2574, respectively.
  • Price ranges: Actual trade prices spanned $63.67 to $63.83 for the first tranche, $64.01 to $64.87 for the second, and $64.88 to $65.875 for the third.
  • Remaining ownership: Following the transactions, Taich directly beneficially owned 316,344 shares of Class A Common Stock.
  • 10b5-1 plan: According to the filing, all sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026.
  • Signed by attorney-in-fact: The form was signed by Randy Wu as attorney-in-fact for Adam Taich on September 11, 2026.

10x Genomics CFO Share Sales Under Pre-Established Trading Plan

According to the Form 4 filed with the SEC, Adam Taich, the Chief Financial Officer of 10x Genomics, Inc., sold a combined total of 46,388 shares of the company's Class A Common Stock on September 9, 2026. The filing states that all transactions were carried out under a Rule 10b5-1 trading plan that Taich adopted on June 10, 2026. The filing also indicates the "X" checkbox was marked to reflect that the transactions were made pursuant to such a plan, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

The sales occurred in three separate tranches. The first involved 1,206 shares at a weighted average price of $63.6774, with individual trade prices ranging from $63.67 to $63.83. The second tranche covered 31,428 shares at a weighted average of $64.3097, with prices from $64.01 to $64.87. The third tranche consisted of 13,754 shares at a weighted average of $65.2574, with prices from $64.88 to $65.875. Each weighted average price reflects execution across multiple trades, and the filing notes that full per-trade detail is available upon request from the SEC, the issuer, or a security holder.

After the reported transactions, the filing shows Taich directly and beneficially owned 316,344 shares of Class A Common Stock. No derivative securities transactions were reported in the filing. The form was filed on September 11, 2026, and signed by Randy Wu as attorney-in-fact for Adam Taich.

What Was Disclosed

The filing disclosed three open-market sales of Class A Common Stock by the CFO of 10x Genomics, Inc. on September 9, 2026, totaling 46,388 shares across weighted average prices between $63.6774 and $65.2574, all under a pre-established Rule 10b5-1 plan.